Dr. Diaz on Pembrolizumab for CRC

Luis A. Diaz, MD
Published: Monday, Jun 19, 2017



Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the impact of pembrolizumab (Keytruda) in patients with colorectal cancer (CRC).

In KEYNOTE-016, only 12 patients with CRC were reported, and it achieved a breakthrough therapy designation status by the FDA, explains Diaz. This led to pembrolizumab being investigated throughout multiple tumor types and it has demonstrated potent efficacy throughout.

Overall, patients with CRC being treated with pembrolizumab are experiencing a benefit, states Diaz.
 


Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the impact of pembrolizumab (Keytruda) in patients with colorectal cancer (CRC).

In KEYNOTE-016, only 12 patients with CRC were reported, and it achieved a breakthrough therapy designation status by the FDA, explains Diaz. This led to pembrolizumab being investigated throughout multiple tumor types and it has demonstrated potent efficacy throughout.

Overall, patients with CRC being treated with pembrolizumab are experiencing a benefit, states Diaz.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x